2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways - PubMed (original) (raw)
Practice Guideline
2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
Sandeep R Das et al. J Am Coll Cardiol. 2018.
No abstract available
Keywords: ASCVD; Expert Consensus Decision Pathway; GLP-1RA; SGLT2 inhibitor; T2D; cardiovascular risk reduction; diabetes.
Figures
FIGURE 1. Summary Graphic
*Most trials of SGLT2i and GLP-1RA required baseline A1C ≥7% (Example: EXSCEL Trial required HbA1c ≥ 6.5%), and most patients were already on metformin as first-line therapy if tolerated and not contraindicated Abbreviations: ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; GLP-1RA = glucagon-like peptide-1 receptor agonist; SGLT2 = sodium-glucose cotransporter-2; T2D = type 2 diabetes.
FIGURE 2. Approach to Managing Patients With Established ASCVD and T2D
*SGLT2 inhibitors and GLP-1RA have not been studied in and do not have an FDA -approved indication for patients with type 1 diabetes. †Some cardiovascular outcome trials included primary prevention patients with multiple risk factors for ASCVD. ‡ The available evidence for cardiovascular event reduction in patients with T2D and clinical ASCVD is derived from trials in which most participants were treated with metformin at baseline. Please see “Do Patients Need to Be on Metformin Before Initiating an SGLT2 Inhibitor or a GLP-1RA?” section in text. **Please see Table 12 and Table 13. If A1C well-controlled at baseline, or known history of frequent hypoglycemic events, reduce dose of sulfonylurea by 50% or basal insulin dose by 20% when starting therapy. Abbreviations: ASCVD = atherosclerotic cardiovascular disease; ESRD = end-stage renal disease; FDA = Food and Drug Administration; GLP-1RA = glucagon-like peptide-1 receptor agonist; SGLT2 = sodium-glucose cotransporter-2; T2D = type 2 diabetes; y/o = years old
Similar articles
- 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.
Das SR, Everett BM, Birtcher KK, Brown JM, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire M, Morris PB, Neumiller JJ, Sperling LS. Das SR, et al. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. J Am Coll Cardiol. 2020. PMID: 32771263 Free PMC article. No abstract available. - 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.
Writing Committee; Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. Writing Committee, et al. J Am Coll Cardiol. 2016 Jul 5;68(1):92-125. doi: 10.1016/j.jacc.2016.03.519. Epub 2016 Apr 1. J Am Coll Cardiol. 2016. PMID: 27046161 Review. No abstract available. - 2022 ACC Expert Consensus Decision Pathway for Integrating Atherosclerotic Cardiovascular Disease and Multimorbidity Treatment: A Framework for Pragmatic, Patient-Centered Care: A Report of the American College of Cardiology Solution Set Oversight Committee.
Writing Committee; Birtcher KK, Allen LA, Anderson JL, Bonaca MP, Gluckman TJ, Hussain A, Kosiborod M, Mehta LS, Virani SS. Writing Committee, et al. J Am Coll Cardiol. 2023 Jan 24;81(3):292-317. doi: 10.1016/j.jacc.2022.08.754. Epub 2022 Oct 25. J Am Coll Cardiol. 2023. PMID: 36307329 No abstract available.
Cited by
- Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients.
Unlu O, Bhatt AS, Blood AJ. Unlu O, et al. JACC Adv. 2024 Jun 4;3(7):101024. doi: 10.1016/j.jacadv.2024.101024. eCollection 2024 Jul. JACC Adv. 2024. PMID: 39129982 Free PMC article. Review. - Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Elshaer A, Chascsa DMH, Lizaola-Mayo BC. Elshaer A, et al. Life (Basel). 2024 Jul 3;14(7):844. doi: 10.3390/life14070844. Life (Basel). 2024. PMID: 39063598 Free PMC article. Review. - A sensitivity indicator screening and intelligent classification method for the diagnosis of T2D-CHD.
Li J, Ying C. Li J, et al. Front Cardiovasc Med. 2024 Apr 24;11:1358066. doi: 10.3389/fcvm.2024.1358066. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38720918 Free PMC article. - Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy.
Van Dril E, Allison M, Schumacher C. Van Dril E, et al. Am Heart J Plus. 2022 Jul 2;17:100163. doi: 10.1016/j.ahjo.2022.100163. eCollection 2022 May. Am Heart J Plus. 2022. PMID: 38559880 Free PMC article. - Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.
Cimino G, Vaduganathan M, Lombardi CM, Pagnesi M, Vizzardi E, Tomasoni D, Adamo M, Metra M, Inciardi RM. Cimino G, et al. ESC Heart Fail. 2024 Apr;11(2):649-661. doi: 10.1002/ehf2.14560. Epub 2023 Dec 13. ESC Heart Fail. 2024. PMID: 38093506 Free PMC article. Review.
References
- American Diabetes Association. Statistics About Diabetes: American Diabetes Association; Available at: http://www.diabetes.org/diabetes-basics/statistics/. Accessed January 29, 2018.
- Rawshani A, Rawshani A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;377:300–1. - PubMed
- Professional Practice Committee. Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41:S3. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical